Axsome Therapeutics to acquire Sunosi from Jazz Pharmaceuticals
Axsome Therapeutics has agreed to acquire Sunosi (solriamfetol), an approved dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), from Jazz Pharmaceuticals. Sunosi is indicated to improve wakefulness in adults having excessive daytime sleepiness (EDS) because of narcolepsy or obstructive sleep apnea (OSA). The DNRI was approved in 2019 by the US Food and Drug Administration (FDA) […]